CDX2 and colorectal carcinoma: Our clinical data are in line with the proposed predictive value of CDX2 for adjuvant chemotherapy in stage III CRC (Dalerba et al., 2016) and show that loss of CDX2 appears to be associated with a higher 5‐year RFS rate after chemotherapy, independent of MSI status.